Rafael L.
- Country
- Spain
- Department
- Service of Infectious Diseases
Research Overview
- Evaluation of Rifamycin-Based Regimens: Isoniazid Plus Rifapentine, Rifampicin, and Isoniazid Plus Rifampicin for Latent Tuberculosis in End-Stage Kidney Disease
- Evaluation of High-Dose Rifampicin, Moxifloxacin, and Linezolid Regimen in Bacilliferous Pulmonary Tuberculosis: A Randomized Controlled Trial
Data & Insights
Has run more than one trial at 3 of 14 partner sites.
Specializations
Tuberculosis Management
This investigator specializes in developing innovative treatment approaches for pulmonary tuberculosis, with particular emphasis on drug-resistant variants and complex cases.
- Bacilliferous Pulmonary TB Treatment
- Drug-Resistant TB Management
- Advanced Treatment Protocols
Their research encompasses optimizing antibiotic combinations for enhanced therapeutic outcomes in tuberculosis treatment.
Renal Complications
The investigator focuses on treating tuberculosis in patients with end-stage kidney disease, addressing the unique challenges of managing concurrent conditions.
- Latent TB in Renal Disease
- Therapeutic Adaptations
- Complex Patient Care
Their work involves developing specialized treatment protocols for patients with compromised renal function.
Antimicrobial Innovation
Research interests include the development of optimized antibiotic regimens, particularly focusing on rifamycin-based treatments and their applications.
- Novel Drug Combinations
- Treatment Duration Optimization
- Patient-Specific Protocols
The investigator explores various antimicrobial combinations to enhance treatment efficacy and patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.